Washington, DC (November 29, 2022) – Promising new data released today indicate that help could soon be on the way for people living in the early stages of Alzheimer’s. During the Clinical Trials on Alzheimer’s Disease (CTAD) conference, Eisai presented full findings from Phase 3 clinical trials of lecanemab, which continues to show promise as a new treatment for Alzheimer’s disease.

Specifically, the data showed the drug reduced functional decline experienced by Alzheimer’s patients by 37 percent over 18 months, compared to placebo. Meanwhile, safety issues appeared to be manageable and will be further studied.

UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement in response to Eisai’s announcement:

“This is incredibly exciting news, even better than what was released just two months ago because it points directly to the impact of this treatment on the lives of people living with Alzheimer’s. People in the early stages of Alzheimer’s and their loved ones have fresh hope thanks to today’s news because slowing the progression of this terrible disease will allow patients to live longer while preserving their quality of life for a longer period of time.

"While most of the treatments currently in the pipeline attack amyloid in the brain, we know that each one works differently. It is our hope the Food and Drug Administration and the Centers for Medicare and Medicaid Services keep that in mind as they evaluate whether to approve this drug and determine whether Medicare will cover it. On the heels of today’s announcement, patients deserve nothing less than to have confidence that the approval process is fair and free from bias.

The Food and Drug Administration is expected to announce by January 6 whether it will grant accelerated approval to lecanemab as Eisai and its partner, Biogen, prepare to seek traditional approval later in 2023.

About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.